QTc interval and scintigraphically assessed myocardial perfusion in newly diagnosed and long-term type 1 diabetes mellitus

Journal of Diabetes and its Complications

Volumn 14, Issue 2, 2000, Pages 90-95

  Meier, M ^a,b   Muhr, D ^b   Weiss, M ^c   Tatsch, K ^c   Standl, E ^a,b   Schnell, O ^a,b  

^a Klinikum Schwabing   (Germany)

^b INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Heart rate corrected QT interval; Tc 99 methoxyisobutylisonitrile (Tc 99m MIBI) scintigraphy; Type 1 diabetes mellitus; Vascular complications

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE PERFUSION; HEART RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; QT INTERVAL; RR INTERVAL; SCINTIGRAPHY; SUDDEN DEATH;

ADULT; CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 1; FEMALE; HEART; HEART RATE; HUMANS; MALE; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TIME FACTORS;

EID: 0034603295     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(00)00055-6     Document Type: Article

References (35)

1. Ahnve S., Gilpin E., Madsen E.B., Froehlicher V., Henning H., Ross J. Prognostic importance of QTc interval at discharge after acute myocardial infarction: a multicenter study of 865 patients. Am Heart J. 108:1984;395-400.
2. Algra A., Tijissen J., Roelandt J., Pool J., Lubsen J. QTc prolongation measured by standard 12 lead electrocardiogram is an independent risk factor for sudden death. Circulation. 83:1991;1888-1894.
3. Bazett H.C. An analysis of the time relations of electrocardiograms. Heart. 7:1920;353-370.
4. Bravenboer B., Hendriksen P.H., Oey L.P., Gipsen W.H., Huffelen A.C., Erkelens D.W. Is the corrected QT interval a reliable indicator of the severity of diabetic autonomic neuropathy? Diabetes Care. 16:1993;1249-1253.
5. Brown K.A. Prognostic value of myocardial perfusion imaging: state of the art and new developments. J Nucl Cardiol. 3:1996;516-537.
6. Busjahn A., Knoblauch H., Faulhaber H.D., Boeckel T., Rosenthal M., Uhlmann R., Hoehe M., Schuster H., Luft F.C. QT interval is linked to 2 long-QT syndrome loci in normal subjects. Circulation. 99:1999;3161-3614.
7. Caner B., Beller G.A. Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocardial viability? Clin Cardiol. 21:1998;235-242.
8. Claus D., Feistel H., Brunholzl C., Platsch G., Neundorfer B., Wolf F. Investigation of parasympathetic and sympathetic cardiac innervation in diabetic neuropathy: heart rate variation versus meta-iodo-benzylguanidine measured by single photon emission computed tomography. Clin Auton Res. 4:1994;117-123.
9. Crane P., Laliberte R., Hemingway S., Thoolen M., Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med. 20:1993;20-25.
10. Dekker J.M., Schouten E.G., Klootwijk P., Pool J., Kromhout D. Association between QT interval and coronary heart disease in middle-aged and elderly men: the Zutphen study. Circulation. 90:1994;779-785.
11. Ewing D.J., Boland O., Neilson J.M.M., Cho C.G., Clarke B.F. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia. 34:1991;182-185.
12. Ewing D.J., Clarke B.F. Diagnosis and management of diabetic autonomic neuropathy. Br Med J. 285:1982;916-918.
13. Heo J., Hermann G.A., Iskandrian A.S., Askenase A., Segal B.L. New myocardial perfusion imaging agents: description and applications. Am Heart J. 1988;1111-1117.
14. Kreiner G., Wolzt M., Fasching P., Leitha T., Edlmayer A., Korn A., Waldhausl W., Dudczak R. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM: comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes. 44:1995;543-549.
15. Landgraf R., Haslbeck M. Diagnose und Differentialdiagnose. Mehnert H., Standl E., Usadel K.H. Diabetologie in Klinik und Praxis. 4th edn. 1999;71-102 Thieme Verlag, Stuttgart.
16. Langer A., Freeman M.R., Josse R.G., Armstrong P.W. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 25:1995;610-618.
17. Mantysaari M., Kuikka J., Mustonen J., Tahvanainen K., Vanninen E., Lansimies E., Uusitupa M. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine. Diabetes. 41:1992;1069-1075.
18. Okada R.D., Glover D., Gaffney T., Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation. 77:1988;491-498.
19. Ong J.J.C., Sarma J.S.M., Venkataraman K., Levin S.R., Singh B.N. Circadian rhythmicity of heart rate and QTc interval in diabetic autonomic neuropathy: implications for the mechanism of sudden death. Am Heart J. 125:1993;744-752.
20. Piwnica-Worms D., Kronauge J.F., Chiu M.L. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation. 82:1990;1826-1838.
21. Rose G.A., Blackhorn H., Gilum R.F., Prineas R.J. Cardiovascular Survey Methods. 2nd edn. 1982;World Health Organization, Geneva. monograph no. 56.
22. Saha G.B., MacIntyre W.J., Brunken R.C., Go R.T., Raja S., Wong C.O., Chen E.Q. Present assessment of myocardial viability by nuclear imaging. Semin Nucl Med. 26:1996;315-335.
23. Sawicki P.T., Dahne R., Bender R., Berger M. Prolonged QT interval as a predictor of mortality in diabetic nephropathy. Diabetologia. 39:1996;77-81.
24. Schnell O., Kirsch C.M., Stemplinger J., Haslbeck M., Standl E. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia. 38:1995;1345-1352.
25. Schnell O., Muhr D., Weiss M., Dresel S., Haslbeck M., Standl E. Reduced myocardial 123-I-Metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes. 45:1996;801-805.
26. Schnell O., Stenner T., Standl E., Haslbeck M. Diagnostischer Wert des frequenzkorrigierten QT-Intervalls bei langjährigem Diabetes mellitus Typ I. Dtsch Med Wochenschr. 121:1996;819-822.
27. Schouten E.G., Dekker J.M., Meppelink P., Kok F.J., Vandenbroucke J.P., Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation. 84:1991;1516-1523.
28. Schwartz P.J., Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 57:1978;1074-1077.
29. Sivieri R., Veglio M., Chinaglia A., Scaglione P., Cavallo-Perin P. Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. Diabetes Med. 10:1993;920-924.
30. Surawicz B., Knoebel S.B. Long QT: good, bad or indifferent? J Am Coll Cardiol. 4:1984;398-413.
31. Veglio M., Borra M., Stevens L.K., Fuller J.H., Perin P.C. The relation between QTc interval prolongation and diabetic complications: The EURODIAB EURODIAB IDDM Complications Study Group. Diabetologia. 42:1999;68-75.
32. Veglio M., Chinaglia A., Borra M., Perin P.C. Does abnormal QT interval prolongation reflect autonomic dysfunction in diabetic patients? QTc interval measure versus standardized tests in diabetic autonomic neuropathy. Diabetes Med. 12:1995;302-306.
33. Ward D.E. Prolongation of the QT interval as an indicator of risk of a cardiac event. Eur Heart J. 9(Suppl. 6):1988;139-144.
34. Zareba W., Moss A.J., Schwartz P.J., Vincent G.M., Robinson J.L., Priori S.G., Benhorin J., Locati E.H., Towbin J.A., Keating M.T., Lehmann M.H., Hall W.J. Influence of genotype on the clinical course of the long-QT syndrome: International Long-QT Syndrome Registry Research Group. N Engl J Med. 339:1998;960-965.
35. Ziegler D., Laux G., Dannehl K., Spuler M., Muhlen H., Mayer P., Gries F.A. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabetes Med. 9:1992;166-175.